Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: A path to novel therapeutic approaches for human disease

Blood

Volumn 122, Issue 23, 2013, Pages 3778-3783

  Bernot, Kelsie M ^a   Nemer, John S ^a   Santhanam, Ramasamy ^a   Liu, Shujun ^b   Zorko, Nicholas A ^a   Whitman, Susan P ^a   Dickerson, Kathryn E ^a,c   Zhang, Mengzi ^a,d   Yang, Xiaojuan ^a,d   McConnell, Kathleen K ^a   Ahmed, Elshafa H ^a   Muñoz, Maura R ^a   Siebenaler, Ronald F ^a   Marcucci, Gabriel G ^a   Mundy Bosse, Bethany L ^a   Brook, Daniel L ^a   Garman, Sabrina ^a   Dorrance, Adrienne M ^a   Zhang, Xiaoli ^a,d   Zhang, Jianying ^a,d   Lee, Robert J ^a,d   Blum, William ^a,e   Caligiuri, Michael A ^a,d,e   Marcucci, Guido ^a,d,e   more..

^a OHIO STATE UNIVERSITY   (United States)

^b University of Minnesota Hormel Institute   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DNA METHYLTRANSFERASE; FLT3 LIGAND; LIPOSOME; MICRORNA 29B; MIXED LINEAGE LEUKEMIA PROTEIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CD135 ANTIGEN; DRUG CARRIER; FLT3 PROTEIN, MOUSE; HISTONE LYSINE METHYLTRANSFERASE; MICRORNA; MIRN29 MICRORNA, MOUSE; MLL PROTEIN, MOUSE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; RNA;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENCAPSULATION; EX VIVO STUDY; GENE EXPRESSION; GENE MUTATION; IN VIVO STUDY; LEUKEMIA REMISSION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DNA METHYLATION; GENETICS; HUMAN; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; TANDEM REPEAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DNA METHYLATION; DRUG CARRIERS; FMS-LIKE TYROSINE KINASE 3; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOID, ACUTE; LIPOSOMES; MICE; MICE, MUTANT STRAINS; MICRORNAS; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROTEASOME INHIBITORS; PYRAZINES; RNA, NEOPLASM; TANDEM REPEAT SEQUENCES;

EID: 84892879433     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-507426     Document Type: Article

References (29)

1. Ley TJ. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
2. Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30(36):4515-4523.
3. Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998;58(1):55-59.
4. Dorrance AM, Liu S, Yuan W, et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest. 2006;116(10):2707-2716.
5. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17(18): 2298-2307.
6. Faber J, Krivtsov AV, Stubbs MC, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009;113(11): 2375-2385.
7. Whitman SP, Hackanson B, Liyanarachchi S, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008;112(5):2013-2016.
8. Bernot KM, Siebenaler RF, Whitman SP, et al. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML [published online ahead of print May 10, 2013]. Leukemia.
9. Zhang Y, Yan X, Sashida G, et al. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood. 2012; 120(5):1118-1129.
10. Dorrance AM, Liu S, Chong A, et al. The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. Blood. 2008;112(6):2508-2511.
11. Gilliland DG. Hematologic malignancies. Curr Opin Hematol. 2001;8(4):189-191.
12. Whitman SP, Ruppert AS, Marcucci G, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007;109(12):5164-5167.
13. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19(8):1345-1349.
14. Lee BH, Tothova Z, Levine RL, et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007;12(4):367-380.
15. Zorko NA, Bernot KM, Whitman SP, et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood. 2012;120(5):1130-1136.
16. Liu S, Wu LC, Pang J, et al. Sp1/NFkappaB/HDAC/ miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17(4):333-347.
17. Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008;111(4):2364-2373.
18. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119(25):6025-6031.
19. Huang X, Schwind S, Yu B, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 2013;19(9): 2355-2367.
20. Garzon R, Heaphy CE, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009;114(26):5331-5341.
21. Mishra A, Liu S, Sams GH, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012;22(5):645-655.
22. Kim YK, Yeo J, Kim B, Ha M, Kim VN. Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. Mol Cell. 2012;46(6):893-895.
23. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411-6418.
24. Xiong Y, Li Z, Ji M, et al. MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. Br J Haematol. 2011;153(6):753-757.
25. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010; 107(16):7473-7478.
26. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias [published correction appears in Clin Cancer Med. 2004;10(22)7787]. Clin Cancer Res. 2004;10(10):3371-3376.
27. Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446-1454.
28. Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31(7):923-929.
29. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8):2301-2307.